Lung cancer (Amsterdam, Netherlands)HumansMaleFemaleAnaplastic Lymphoma KinaseLung Neoplasms
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Hannah Le, Josh Coulter, Ken Culver, Joseph C Cappelleri, Nada Rifi, Hui Lu, Matthew Quaife, Keila Meginnis, Gabriela S Fernandez, Shailja Vaghela, Brett Hauber, Thomas E Stinchcombe
Published: 202610.1016/j.lungcan.2025.108850
Abstract
PURPOSE: Next-generation anaplastic lymphoma kinase (ALK)-targeting tyrosine kinase inhibitors (TKIs) are standard first-line (1L) treatments for ALK+ advanced non-small cell lung cancer (aNSCLC). Treatments differ in systemic and central nervous sys…
Preview only. Read the full abstract at the source